Zoledronic Acid in the Treatment of Breast Cancer With Minimal Residual Disease in the Bone Marrow

NCT00172068 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

96

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Breast Cancer

Interventions

DRUG: Zoledronic acid + Calcium/Vitamin D

Sponsor

Novartis Pharmaceuticals